Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis (Q66034912)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis |
clinical trial |
Statements
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis (English)
0 references
16 February 2004
0 references
28 November 2006
0 references
764
0 references
18 year
0 references
60 year
0 references